Genetic Test Evaluation

understanding how genetic tests impact patient management

CYP2C19 Pharmacogenomic Genotyping to Direct Clopidogrel Therapy for Secondary Prevention in Patients with a History of Stroke and/or Transient Ischemic Attack (TIA)

November 14, 2017

This report evaluates the clinical utility for CYP2C19 pharmacogenomic genotyping to direct clopidogrel therapy for secondary prevention in adult patients who have experienced a stroke or transient ischemic attack (TIA).